Article Text

FRI0096 Haq baseline values in an international registry of ra patients during the era of biologic terapies: the 2013 meteor database.
  1. G. Ferraccioli1,
  2. G. Lapadula2,
  3. M. Dougados3,
  4. D. J. Veale4,
  5. T. W. Huizinga5,
  6. C. F. Allaart5,
  7. R. B. Landewé6,
  8. J. A. P. Da Silva7,
  9. E. Martin Mola8,
  10. R. J. Moots9,
  11. J. Kay10,
  12. K. I. Salomon-Escoto10,
  13. D. van der Heijde5
  1. 1Division Of Rheumatology, Institute Of Rheumatology And Affine Sciences, Catholic University Of The Sacred Heart, Rome
  2. 2Rheumatology Unit, University Medical School of Bari, Bari, Italy
  3. 3Paris-Descartes University, Department of Rheumatology B, APHP, Cochin Hospital, Paris, France
  4. 4Department of Rheumatology, St Vincent’s University Hospital, Dublin Academic Medical Centre, Dublin, Ireland
  5. 5Department of Rheumatology, Leiden University Medical Center, Leiden
  6. 6Department of Clinical Immunology & Rheumatology, Academic Medical Centre / University of Amsterdam, Amsterdam, Netherlands
  7. 7Rheumatology Department, University of Coimbra, Coimbra, Portugal
  8. 8Rheumatology Department, Hospital Universitario La Paz, Universidad Autónoma, Madrid, Spain
  9. 9Rheumatology, Aintree University Hospital, Liverpool, United Kingdom
  10. 10Rheumatology Center, University of Massachusetts Medical School, Worcester, United States


Background HAQ score is a major index of rheumatoid arthritis (RA) disease severity in clinical practice. Data indicate that patients with RA and high HAQ scores (>2) receive disability benefits (1). We investigated the proportion of patients with no and severe disability (HAQ>2) (2,3) during the era of biologic therapies in a large international database. This query provides “real world” data about the burden of disability associated with RA in different clinical settings and in different cohorts.

Objectives To assess the proportions of RA patients with no and severe disability across various countries.

Methods The METEOR database is an international database that has recruited RA patients from different countries who are followed in the setting of usual care at various centres. We report the number of patients in this database (Table 1) and we analyzed the proportion of RA patients for whom all values have been entered, considering the different characteristics across participating countries.

Conclusions This cross-sectional study suggests that, especially in the UK and Italy, RA patients with HAQ scores<0.5 at entry into the database are in the minority and that there remains a not insignificant number of subjects with a HAQ score >2. This suggests that there may still be an opportunity to treat RA more aggressively in some countries. Further studies are warranted to determine whether this reflects barriers to successful treatment of RA that may be inherent in some health care systems or if it is merely an indication of structural damage from past disease activity.


  1. Kirwan J et al. British J of Rheum 1986; 25:206-209

  2. Krishnan E et al. Arth Rheum 2004; 50: 953-960

  3. Mancarella L et al. J Rheumatol 2007; 34:1670-1673

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.